$PTCT News

Morgan Stanley Maintains Overweight on PTC Therapeutics, Raises Price Target to $104

Wells Fargo Maintains Overweight on PTC Therapeutics, Raises Price Target to $106

PTC Therapeutics, Inc. (PTCT) Q2 2026 Earnings Call Transcript

PTC Therapeutics (NASDAQ:PTCT) Soars on Q2 Earnings Beat and Raised Guidance

PTC Therapeutics Raises FY2026 Sales Guidance from $1.080B-$1.180B to $1.180B-$1.280B vs $1.196B Est

Wells Fargo Maintains Overweight on PTC Therapeutics, Lowers Price Target to $93

Cantor Fitzgerald Maintains Overweight on PTC Therapeutics, Raises Price Target to $130

RBC Capital Maintains Sector Perform on PTC Therapeutics, Raises Price Target to $85

The Prognosis For PTC Therapeutics

PTC Therapeutics Announces Proposed Private Placement Of $500M Of Convertible Senior Notes Due 2031

PTC THERAPEUTICS INC (NASDAQ:PTCT) Scores Perfect 10/10 For Technical Breakout Setup

PTC Therapeutics, Inc. (PTCT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Jefferies Upgrades PTC Therapeutics to Buy, Raises Price Target to $85

PTC Therapeutics, Inc. (PTCT) Presents at Bank of America Global Healthcare Conference 2026 Transcript

PTC Therapeutics: Sephience Turns The Story From Regulatory Repair To Operating Leverage

PTC Therapeutics Q1 Earnings Call Highlights

TD Cowen Upgrades PTC Therapeutics to Buy, Raises Price Target to $90

RBC Capital Maintains Sector Perform on PTC Therapeutics, Raises Price Target to $82

PTC Therapeutics, Inc. Q1 2026 Earnings Call Summary

Wells Fargo Maintains Overweight on PTC Therapeutics, Raises Price Target to $95